Top team with senior management experience in Pharma industry

Radan Spaventi, MD, PhDRadan

Foto: Pixell

Phone: +385 91 4351 000
E-mail: radan.spaventi@tdltp.com
Skype: radan62
URL: http://www.linkedin.com/pub/radan-spaventi/3/b80/481

  • 20+ years experience in Pharma industry
    • SVP & Exec Team Member, Galapagos (Belgium)
    • VP, Head of Macrolide CEDD, GlaxoSmithKline (UK)
    • Global Drug Discovery Leadership Team member, GlaxoSmithKline (UK)
    • CEO, GSK Research Centre Zagreb (Croatia)
    • CSO and Board Member, Odyssey Pharmaceuticals (US)
    • CSO and Board Member, PLIVA (Croatia)
    • CEO, PLIVA Research Institute (Croatia)
  • Successful track record in setting up corporate strategies and leading strategic transformations
  • Extensive experience in leading top class international life sciences R&D teams and organizations
  • Extensive experience in business development, M&A activities, strategic alliances and investor relationships
  • Broad knowledge and understanding of global pharmaceutical industry trends
  • Medical degree and a PhD in medical sciences from the University of Zagreb, Croatia; post-doc at Dana Faber Cancer Institute and Harvard Medical School, Boston, US
  • Author of more than 50 scientific papers and the author/editor of four books.

Katarina Orešković, MD, PhDKatarina

Phone: +385 98 404 227
E-mail: katarina.oreskovic@tdltp.com
Skype: katarina.oreskovic1
URL: http://www.linkedin.com/pub/katarina-oreskovic/60/541/595

  • 20+ years experience in Pharma industry
    • VP, R&D Interface, Galapagos (Belgium)
    • Clinical pharmacology and discovery medicine (CPDM) Director, GlaxoSmithKline (UK)
    • Global CPDM Leadership Team member, GlaxoSmithKline (UK)
    • Drug Discovery Global Safety Board member, GlaxoSmithKline (UK)
    • Business and product development Director, PLIVA Research Institute (Croatia)
    • Clinical Research Director, PLIVA (Croatia)
    • Associate in Marketing and Medical Affairs
  • Expertise in drug discovery, translational science, and early drug development
  • Proficiency in clinical trial design, set-up, management and reporting, including medical monitoring
  • Expertise in therapeutic areas of infection, inflammation and oncology
  • Deep understanding of pharmaceutical industry, with experience in various areas of the business including
    • R&D
    • Business development (from partnerships, over licensing to corporate transactions)
    • Medical affairs
    • Marketing
  • Medical degree and a PhD in pharmacology from the University of Zagreb, Croatia
  • Author of over 20 scientific papers and numerous conference reports

Our track record

Pharmaceutical R&D

  • 25+ drug discovery projects
  • 20+ drug development projects (early development of innovative drugs)
    • TAs: Infection, Inflammation, Hematology and Oncology
    • Small molecules and peptides
    • Oral, intravenous, dermal and rectal routes
    • Clinical trials in CEE, Western Europe, US and Canada

50+ generics development projects, including 2 biosimilars

Business development

15+ licensing and partnering deals across pharma industry

10+ successful M&A projects during PLIVA global expansion

Succesfull spin-out of proprietary R&D from PLIVA

Successful sell of PLIVA Research Institute to GSK with rapid integration into GSK organisation

Successful sell of GSK Research Centre Zagreb to Galapagos with a steering role in the process of integration

Over 70 publications

Infectous diseases

Pene Dumitrescu T, Anić-Milić T, Orešković K, Padovan J, Brouwer KL, Zuo P, Schmith VD. Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother 2013; 57: 3194-3201.

Starčević K, Pešić D, Toplak A, Landek G, Alihodžić S, Herreros E, Ferrer S, Spaventi R, Perić M. Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. Eur J Med Chem 2012; 49: 365-378.

Perić M, Fajdetić A, Rupčić R, Alihodžić S, Žiher D, Bukvić Krajačić M, Smith KS, Ivezić-Schonfeld Z, Padovan J, Landek G, Jelić D, Hutinec A, Mesić M, Ager A, Ellis WY, Milhous WK, Orth C, Spaventi R. Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. J Med Chem 2012; 55: 1389-1401.

Pešić D, Starčević K, Toplak A, Herreros E, Vidal J, Almela MJ, Jelić D, Alihodžić S, Spaventi R, Perić M. Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides. J Med Chem 2012; 55: 3216-3227.

Bukvić Krajačić M, Perić M, Smith KS, Ivezić Schonfeld Z, Žiher D, Fajdetić A, Kujundžić N, Schonfeld W, Landek G, Padovan J, Jelić D, Ager A, Milhous WK, Ellis W, Spaventi R, Orth C. Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. J Med Chem 2011; 54: 3595-3605.

Fajdetić A, Vinter A, Čipčić Paljetak H, Padovan J, Palej Jakopović I, Kapić S, Alihodžić S, Filić D, Modrić M, Košutić-Hulita N, Antolović R, Ivezić Schonfeld Z, Mutak S, Eraković Haber V, Spaventi R. Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones. Eur J Med Chem 2011; 46: 3388-3397.

Fajdetić A, Čipčić Paljetak H, Layarevski G, Hutinec A, Alihodžić S, Đerek M, Štimac V, Andreotti D, Šunjić V, Berge JM, Mitak S, Dumić M, Lociuro S, Holmes DJ, Maršić N, Eraković Haber V, Spaventi R. 4“-O-(omega-Quinolylamino-alkzlamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. Bioorg Med Chem 2010; 18: 6559-6568.

Brajša K, Ferenčić Ž, Katičić M, Bošnjak B, Presečki V, Spaventi R, Dominis M. Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. Acta Clin Croat 2008; 47: 123-127.

Brajša K, Ferenčić Ž, Katičić M, Radošević S, Presečki V, Spaventi R, Dominis M. Influence of H. pylori infection and eradication on p53, c-erbB-2, and Ki-67 in gastric mucosa. Hepatogastroenterology 2006; 53: 960-964.

Parnham MJ, Bogaards JJP, Schrander F, Schut MW, Orešković K, Mildner B. The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro. Biopharm Drug Dispos 2005; 26: 27-33.

Parnham MJ, Orešković K. Antibiotics for asthma? Pediatr Pulmonol (Suppl.) 2004; 26: 52.

Katušic D, Petriček I, Mandić Z, Petrić I, Salopek-Rabatić J, Kružić V, Orešković K, Šikić J, Petriček G. Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. Am J Ophthalmol 2003; 135: 447-451.

PleškoS, Orešković K, Schoenfeld W, Skerlev M, Antolovic R. In vitro assay for activity of PLD-118 against Trychophytonmentagrophytes. .43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, Sep 14-17, 2003.

Hasenohrl A, Orešković K, Maršić N. PLD-118: In vitro Activity on Candida albicans strains – comparison with in vivo efficacy in systemic cadidiasis mouse model.43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, Sep 14-17, 2003.

Schoenfeld W, Mittendorf J, Schmidt A, Geschke U, Orešković K. In vivo efficacy of PLD-118 in mice models of systemic Candida infection. Clin Microbiol Infect 2002; 8 (Suppl. 1): 101.

Schroedter A, Bischoff A, Orešković K, Knoeller J, Schoenfeld W, Peterson J. Tolerability, safety and pharmacokinetics of PLD-118, a novel antifungal compound, after multiple oral dosing in healthy male volunteers. Clin Microbiol Infect 2002; 8 (Suppl. 1): 264.

Schroedter A, Bischoff A, Orešković K, Schoenfeld W, Knoeller J. PLD-118: Tolerability, safety and pharmacokinetics following single oral dose in healthy volunteers. Mycoses 2002; 45 (Suppl. 2): 54.

Kuzman I, Puljiz I, Đakovic-Rode O, Draženović V, Orešković K, Vuković J, Čulig J. The clinical efficacy of azithromycin in the treatment of community-acquired legionnaires' disease: A review of 74 cases. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey, April 1-4, 2001.

Reiner Z, Burek V, Goldner V, Jug M, Zrnić T, Orešković K, Čulig J. Prevalence of antibodies to Chlamydia pneumoniae in patients with coronary artery diseases and acute myocardial infarction. Lijec Vjesn 2000; 122: 263-269 [in Croatian].

Katičić M, Kalenić S, Plečko V, Pavić-Sladoljev D, Prskalo M, Tićak M, Čulig J, Šabarić B, Škurla B, Presečki V, Dominis M, Orešković K. Primary resistance of Helicobacter pylori to macrolides and metronidazole. The Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. Seville, Spain, Jan 26-28, 2000.

Klapan I, Čulig J, Orešković K, Matrapazovski M, Radošević S. Azitromicin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20: 7-11.

Schönwald S, Kuzman I, Burek V, Škerk V, Car V, Čulig J, Orešković K, Radošević S. Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome – A randomized study. Infection 1999; 27: 198-202.

Prpić-Mehičić G, Buntak-Kobler D, Orešković K. Azithromycin versus amoxicillin clavulanate in treatment of odontogenic infections. Int Endod J 1998; 31: 210.

Šimićević V, Erceg D, Dohoczky C, Radošević S, Spaventi R, Buraglio M, Canali S, Čulig J: Lack of effect of food on the bioavailability of oral azithromycin tablets. Clin Drug Invest 1998; 16: 405-410.

Ficnar B, Huzjak N, Orešković K, Matrapazovski M, Klinar I. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. J Chemother 1997; 9: 38-43.

Kuzman I, Orešković K, Schönwald S, Čulig J. Azithromycin in treatment of pneumonias caused by Chlamydia spp: A retrospective study. Int J Clin Pharm Res 1997; 16: 103-107.

Schönwald S, Kuzman I, Car V, Čulig J, Orešković K. Single-dose azithromycin in the treatment of atypical pneumonia: A pilot study. In: Zinner SH (ed.) Infectious disease and therapy, vol. 21, Expanding Indications for the new macrolides, azalides, and streptogramins. New York, US: Marcel Dekker Inc; 1997. p. 634-637.

Kuzman I, Orešković K, Schönwald S, Čulig J, Zrnić T. Azithromycin in the treatment of Q fever. 8th European Congress of Clinical Microbiology and Infectious Diseases, Laussane, Switzerland, May 25-28, 1997.

Kovačić D, Orešković K. EuroTransMed: Bacterial resistance in Europe. Medicus 1997; 6: 111-113 [in Croatian].

Kuzman I, Schönwald S, Čulig J, Orešković K. Azithromycin, erythromycin and doxycycline in the treatment ofMycoplasma pneumoniae pneumonia: A retrospective study. In: Berkarda B (ed.)10th Mediterranean congress of chemotherapy. Bologna, Italy: Monduzzi Editore; 1996, p. 211-214.

Inflammation / Immunology

Polančec D, Vrančić M, Dupont S, Orešković K, Eraković Haber V. Novel flow cytometry method for the detection of neutrophil activation and degranulation in peripheral human whole blood. CYTO 2013: XXVIII Congress of the International society for advancement of cytometry, San Diego, USA, May 19-22, 2013. Beetens Beetens

Beetens J, Vanhoutte F, Namour F, Dupont S, Orešković K, Polančec D, Haazen W, Petkova M, Van Bockstaele D, Van der Aa A, van ’t Klooster G. The FFA2 (GPR43) antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation. Knowledge for Growth, Ghent, Belgium, May 30, 2013.

Polančec D, Vrančić M, Dupont S, Orešković K, Eraković Haber V. Flow cytometric measurement of the CD11b Activated Epitope (AE) expression on human neutrophils in whole blood as a tool in drug development process. CYTO 2013: XXVIII Congress of the International society for advancement of cytometry, San Diego, USA, May 19-22, 2013.

Kapitanović Vidak H, Ćatela Ivković T, Jokić M, Spaventi R, Kapitanović S. The association between proinflammatory cytokine polymorphisms and cerebral palsy in very preterm infants. Cytokine 2012; 58: 57-64.

Bosnar M, Kragol G, Koštrun S, Vujasinović I, Bošnjak B, Bencetić Mihaljević V, Marušić Ištuk Z, Kapić S, Hrvačić B, Brajša K, Tavčar B, Jelić D, Glojnarić I, Verbanac D, Čulić O, Padovan J, Alihodžić S, Eraković Haber V, Spaventi R. N’-substituted-2’-O,3’-N-carbonimidoyl bridged macrolides – novel anti-inflammatory macrolides without antimicrobial activity. J Med Chem 2012; 55: 6111-6123.

Schmith VD, Zuo P, Padovan J, Stephens K, Kulkarni S, Orešković K. Predicting systemic exposure in humans for a novel drug with low oral bioavailability and local action in the gut. J Clin Pharmacol 2010, 50: 1067.

Sabarinath S, Goyal N, Derendorf H, Orešković K, Schmith VD. Modeling of target lesion scores over time in a psoriasis microplaque assay. Clin Pharmacol Ther 2010; 87 (Suppl. 1): S56-S57.

Brajša K, Ferenčić Ž, Katičić M, Bošnjak B, Presečki V, Spaventi R, Dominis M. Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. Acta Clin Croat 2008; 47: 123-127.

Parnham MJ, Čulić O, Eraković V, Munić V, Popović-Grle S, Barišić K, Bosnar M, Brajša K, Čepelak I, Čužić S, Glojnarić I, Manojlović Z, Novak-Mirčetić R, Orešković K, Pavičić-Beljak V, Radošević S, Sučić M. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005; 517: 132-143.

Ruenzi M,Stolte M,Veljača M, Orešković K, Peterson J, and Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128 (Suppl. 2): A584.

Parnham MJ, Orešković K. Antibiotics for asthma? Pediatr Pulmonol (Suppl.) 2004; 26: 52.

Knežević N, Nikolić B, Brajša K, Spaventi R, Jonjić N, Jonjić S, Marušić S. Monoclonal antibodies against maternal major histocompatibility complex class I molecules induce rapid abortion in mice. Am J Reprod Immun 1999; 41: 217-223.

Lukač J, Kovačević D, Krušlin B, Spaventi R, Ferenčić Ž, Belicza M, Desyo D, Kusić Z. Relationship between natural killer (NK) cell activity and erbB-2 expression in colorectal cancer patients. Period Biol 1998; 100: 537-539.

Antica M, Kušić B, Spaventi R, Jakšić B, Vitale B. Functional differences of T cells in B-chronic lymphocytic leukemia. Leuk Lymphoma 1993; 9: 133-140.

Spaventi R, Sabioncello A, Kadrnka-Lovrenčić M, Dekaris D. In vitro detection of cellular immunity to Candida albicans in children. Period Biol 1986; 88 (supp. 1): 277-278.

Oncology

Ćatela Ivković T, Lončar B, Spaventi R, Kapitanović S. Association of H-ras polymorphisms and susceptibility to sporadic colon cancer. Int J Oncol 2009; 35: 1169-1173.

Kapitanović S, Čačev T, Antica M, Kralj M, Cavrić G, Pavelić K, Spaventi R. Effect of indomethacin on E-cadherin and b-catenin expression in HT'29 colon cancer cells. Exp Mol Pathol 2006; 80: 91-96.

Čačev T, Jokić M, Spaventi R, Pavelić K, Kapitanović S. Loss of heterozygosity testing using real-time PCR analysis of single nucleotide polymorphisms. J Cancer Res Clin Oncol 2006; 132: 200-204.

Čačev T, Radošević S, Spaventi R, Pavelić K, Kapitanović S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 2005; 54: 1129-1135.

Popović Hadžija M, Radošević S, Kovačević D, Lukač J, Hadžija M, Spaventi R, Pavelić K, Kapitanović S. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation. Mutat Res 2004; 548: 61-73.

Kapitanović S, Čačev T, Berković M, Popović-Hadžija M, Radošević S, Seiwerth S, Spaventi Š, Pavelić K, Spaventi R. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. J Clin Pathol 2004; 57:1312-1318.

Kapitanović S, Čačev T, Radošević S, Spaventi Š, Spaventi R, Pavelić K.: APC gene loss of heterozygosity, mutations, E1317Q, and I1307K germ-line variants in sporadic colon cancer in Croatia. Exp Mol Pathol 2004; 77(3):193-200.

Kapitanović S, Čačev T, Spaventi R, Pavelić K. Submerged gel electrophoresis on Spreadex gels – a new method for APC gene mutations detection. J Mol Med 2001; 79: 333-337.

Popović Hadžija M, Kapitanović S, Radošević S, Mirt M, Kovačević D, Lukač J, Hadžija M, Spaventi R, Pavelić K. Loss of  heterozygosity of DPC4 tumor supressor gene in human sporadic colon cancer. J Mol Med 2001; 79: 128-132.

Kapitanović S, Radošević S, Slade N, Kapitanović M, Anđelinović Š, Ferenčić Ž, Tavassoli M, Spaventi Š, Pavelić K, Spaventi R. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000; 126: 205-211.

Pavelić K, Kapitanović S, Radošević S, Bura M, Seiwerth S, Pavelić Lj, Spaventi R. Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognisis. J Mol Med 2000; 78: 111-118.

Šturlan S, Kapitanović S, Kovačević D, Lukač J, Spaventi S, Spaventi R, Pavelić K. Loss of heterozigosity of APC and DCC tumor suppressor genes in human sporadic colon cancer. J Mol Med 1999; 77: 316-321.

Ferenčić Ž, Spaventi R, Kovačević D, Troskot B, Lukač J. Synoptic surgical pathology of colorectal cancer. Libri Oncol 1998; 27: 21-26.

Lukač J, Kovačević D, Krušlin B, Spaventi R, Ferenčić Ž, Belicza M, Desyo D, Kusić Z. Relationship between natural killer (NK) cell activity and erbB-2 expression in colorectal cancer patients. Period Biol 1998; 100: 537-539.

Kapitanović S, Radošević S, Kapitanović M, Anđelinović Š, Ferenčić Ž, Tavassoli M, Primorac D, Sonicki Z, Spaventi Š, Pavelić K, Spaventi R. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-1113.

Ferenčić Ž, Spaventi R, Troskot B, Kovačević D, Lukač J. Colorectal cancer staging - An overview. Libri Oncol 1997; 26: 77-82.

Osmak M, Kovaček I, Ljubenkov I, Spaventi R, Eckert-Maksić M. Ascorbic acid and 6-deoxy-6-chloro-ascorbic acid: Potential anticancer drugs. Neoplasma 1997; 44: 101-107.

Kapitanović S, Spaventi R, Vujisić S, Petrović Z, Kurjak A, Pavelić ZP, Gluckman JL, Stambrook PJ, Pavelić K. nm23 -H1 gene expression in ovarian tumors - A potential tumor marker. Anticancer Res 1995; 15: 587-590.

Spaventi R. Genetic basis of tumors of the colon. Lijec Vjesn 1995; 117: 285-293 [in Croatian].

Pečur L, Kapitanović S, Sonicki Z, Pavičić F, Spaventi Š, Gluckman JL, Stambrook PJ, Pavelić ZP, Spaventi R, Pavelić K. Prognostic significance of transforming growth factor alpha (TGF-a) in human lung carcinoma: An immunohistochemical study. Anticancer Res 1994; 14: 2839-2844.

Kapitanović S, Spaventi R, Poljak Lj, Kapitanović M, Pavellić ZP, Gluckman JL, Spaventi Š, Pavelić K. High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect Prev 1994; 18: 97-101.

Spaventi R, Pečur L, Pavelić K, Pavelić ZP, Spaventi Š, Stambrook PJ. Human Tumour Bank in Croatia: A possible model for a small bank as a part of the future European Tumour Bank Network. Eur J Cancer 1994; 30A(3): 419.

Spaventi R, Pavelić K, Pavelić ZP, Gluckman JL. The concomitant expression of oncogenes and growth factors in human breast cancer. Eur J Cancer 1994 30A: 723-724.

Spaventi R, Kamenjicki E, Pećina N, Grazio S, Grazio S, Pavelić J, Kušić B, Cvrtila D, Danilović Ž, Spaventi Š, Pavelić K, Gluckman J, Pavelić ZP. Immunohistochemical detection of TGF-a, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: A concomitant expression?. In Vivo 1994; 8: 183-190.

Kapitanović S, Spaventi R, Kušić B, Pavelić K. c-erbB-2/neu in colorectal carcinoma: a potential prognostic value?. Eur J Cancer 1993; 29A: 170.

Antica M, Kušić B, Spaventi R, Jakšić B, Vitale B. Functional differences of T cells in B-chronic lymphocytic leukemia. Leuk Lymphoma 1993; 9: 133-140.

Pavelić K, Spaventi R, Pečur L, Spaventi Š. Croatian tumor bank – Significance and perspectives. The embryo of the European network of tumor banks? Hrvatska banka tumora - Značaj i perspektive. Zametak Europske mreže tumorskih banaka? Encyclopaedia moderna 1992; 40: 561-563 [in Croatian].

Sever Z, Pavelić J, Levanat S, Spaventi R, Despot-Slade N, Jelić I, Baltić V, Pavelić Lj, Čabrijan T, Časl T, Pavelić K. Insulin-related substances in human solid tumors. Tumordiagn Ther 1992; 13: 54-59.

Pavelić K, Spaventi R (eds.) Molecular oncology. Zagreb, Croatia: Globus and HAZU; 1992. [in Croatian].

Pavelić K, Pećina-Šlaus N, Spaventi R. Growth factors and proto-oncogenes in early mouse embryogenesis. Int J Dev Biol 1991; 35: 209-214.

Čabrijan T, Levanat S, Pekić B, Pavelić J, Spaventi R, Frahm H, Zjačić-Rotkvić V, Goldoni V, Vrbanec D, Misjak M, Grazio S, Pavelić K. The role of insulin-related substance in Hodgkin disease. J Canc Res Clin Oncol 1991; 117: 615-619.

Pačarizi H, Spaventi R, Spaventi Š, Levanat S, Pavelić J, Pavelić K. The expression of growth factors in human melanomas. Tumordiagn Ther 1990; 11: 37-40.

Osmak M, Eckert-Maksić M, Pavelić K, Maksić ZB, Spaventi R, Beketić L, Kovaček I, Šušković B. 6-Deoxy-6-bromo-ascorbic acid inhibits growth of mouse melanoma cells. Res Exp Med 1990; 190: 443-449.

Ikić D, Pavelić K, Spaventi R (eds.). Oncogenes and growth factors. Zagreb, Yugoslavia: Globus and JAZU; 1989 [in Croatian].

Krušlin B, Levanat S, Baltić V, Milković D, Pavelić J, Spaventi R, Spaventi Š, Pavelić K. Growth factors in human tumors. Res Exp Med 1989; 189: 91-99.

Antica M, Spaventi R. Onkogene c-myc in normal and transformed cell. In: Ikić D, Pavelić K, Spaventi R (eds.) Oncogenes and growth factors. Zagreb, Yugoslavia: Globus and JAZU; 1989. p. 65-73 [in Croatian].

Čabrijan T, Pačarizi H, Levanat S, Vrbanec D, Pavelić J, Milković D, Spaventi R, Končar M, Baltić V, Spaventi Š, Pavelić K. Autocrine tumor growth regulation by the insulin growth factor I (IGF I) and the epidermal growth factor (EGF). In: Bresciani F, King RJB, Lippman ME, Raynaud JP (eds.) Progress in cancer research and therapy, vol. 35: Hormones and Cancer 3. New York, US: Raven Press Ltd; 1988. p. 227-230.

Spaventi R, Pavelić K. Oncogenes and growth factors in embryogenesis. In: Baltić V (ed.) Oncogenes and tumor growth factors. Novi Sad, Yugoslavia: Savez društava za borbu protiv raka Vojvodine; 1988. p. 25-48 [in Croatian].

Gastrointestinal diseases

Beetens J, Vanhoutte F, Namour F, Dupont S, Orešković K, Polančec D, Haazen W, Petkova M, Van Bockstaele D, Van der Aa A, van ’t Klooster G. The FFA2 (GPR43) antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation. Knowledge for Growth, Ghent, Belgium, May 30, 2013.

Schmith VD, Zuo P, Padovan J, Stephens K, Kulkarni S, Orešković K. Predicting systemic exposure in humans for a novel drug with low oral bioavailability and local action in the gut. J Clin Pharmacol 2010, 50: 1067.

Ćatela Ivković T, Lončar B, Spaventi R, Kapitanović S. Association of H-ras polymorphisms and susceptibility to sporadic colon cancer. Int J Oncol 2009; 35: 1169-1173. PDF br. 17 u prilogu

Brajša K, Ferenčić Ž, Katičić M, Bošnjak B, Presečki V, Spaventi R, Dominis M. Influence of Helicobacter pylori infection persistence on bcl-2 expression in gastric mucosa inflammatory cells. Acta Clin Croat 2008; 47: 123-127.

Brajša K, Ferenčić Ž, Katičić M, Radošević S, Presečki V, Spaventi R, Dominis M. Influence of H. pylori infection and eradication on p53, c-erbB-2, and Ki-67 in gastric mucosa. Hepatogastroenterology 2006; 53: 960-964.

Kapitanović S, Čačev T, Antica M, Kralj M, Cavrić G, Pavelić K, Spaventi R. Effect of indomethacin on E-cadherin and b-catenin expression in HT'29 colon cancer cells. Exp Mol Pathol 2006; 80: 91-96.

Ruenzi M,Stolte M,Veljača M, Orešković K, Peterson J, and Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128 (Suppl. 2): A584.

Čačev T, Radošević S, Spaventi R, Pavelić K, Kapitanović S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 2005; 54: 1129-1135.

Popović Hadžija M, Radošević S, Kovačević D, a J, Hadžija M, Spaventi R, Pavelić K, Kapitanović S. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation. Mutat Res 2004; 548: 61-73.

Kapitanović S, Čačev T, Berković M, Popović-Hadžija M, Radošević S, Seiwerth S, Spaventi Š, Pavelić K, Spaventi R. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. J Clin Pathol 2004; 57:1312-1318.

Kapitanović S, Čačev T, Radošević S, Spaventi Š, Spaventi R, Pavelić K.: APC gene loss of heterozygosity, mutations, E1317Q, and I1307K germ-line variants in sporadic colon cancer in Croatia. Exp Mol Pathol 2004; 77(3):193-200.

Popović Hadžija M, Kapitanović S, Radošević S, Mirt M, Kovačević D, Lukač J, Hadžija M, Spaventi R, Pavelić K. Loss of  heterozygosity of DPC4 tumor supressor gene in human sporadic colon cancer. J Mol Med 2001; 79: 128-132.

Katičić M, Kalenić S, Plečko V, Pavić-Sladoljev D, Prskalo M, Tićak M, Čulig J, Šabarić B, Škurla B, Presečki V, Dominis M, Orešković K. Primary resistance of Helicobacter pylori to macrolides and metronidazole. The Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. Seville, Spain, Jan 26-28, 2000.

Kapitanović S, Radošević S, Slade N, Kapitanović M, Anđelinović Š, Ferenčić Ž, Tavassoli M, Spaventi Š, Pavelić K, Spaventi R. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000; 126: 205-211.

Šturlan S, Kapitanović S, Kovačević D, Lukač J, Spaventi S, Spaventi R, Pavelić K. Loss of heterozigosity of APC and DCC tumor suppressor genes in human sporadic colon cancer. J Mol Med 1999; 77: 316-321.

Ferenčić Ž, Spaventi R, Kovačević D, Troskot B, Lukač J. Synoptic surgical pathology of colorectal cancer. Libri Oncol 1998; 27: 21-26.

Kapitanović S, Radošević S, Kapitanović M, Anđelinović Š, Ferenčić Ž, Tavassoli M, Primorac D, Sonicki Z, Spaventi Š, Pavelić K, Spaventi R. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-1113.

Ferenčić Ž, Spaventi R, Troskot B, Kovačević D, Lukač J. Colorectal cancer staging - An overview. Libri Oncol 1997; 26: 77-82.

Spaventi R. Genetic basis of tumors of the colon. Lijec Vjesn 1995; 117: 285-293 [in Croatian].

Kapitanović S, Spaventi R, Poljak Lj, Kapitanović M, Pavellić ZP, Gluckman JL, Spaventi Š, Pavelić K. High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect Prev 1994; 18: 97-101.

Kapitanović S, Spaventi R, Kušić B, Pavelić K. c-erbB-2/neu in colorectal carcinoma: a potential prognostic value?. Eur J Cancer 1993; 29A: 170.

Respiratory tract diseases

Parnham MJ, Čulić O, Eraković V, Munić V, Popović-Grle S, Barišić K, Bosnar M, Brajša K, Čepelak I, Čužić S, Glojnarić I, Manojlović Z, Novak-Mirčetić R, Orešković K, Pavičić-Beljak V, Radošević S, Sučić M. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005; 517: 132-143.

Parnham MJ, Orešković K. Antibiotics for asthma? Pediatr Pulmonol (Suppl.) 2004; 26: 52.

Kuzman I, Puljiz I, Đakovic-Rode O, Draženović V, Orešković K, Vuković J, Čulig J. The clinical efficacy of azithromycin in the treatment of community-acquired legionnaires' disease: A review of 74 cases. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey, April 1-4, 2001.

Klapan I, Čulig J, Orešković K, Matrapazovski M, Radošević S. Azitromicin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20: 7-11.

Schönwald S, Kuzman I, Burek V, Škerk V, Car V, Čulig J, Orešković K, Radošević S. Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome – A randomized study. Infection 1999; 27: 198-202.

Ficnar B, Huzjak N, Orešković K, Matrapazovski M, Klinar I. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. J Chemother 1997; 9: 38-43.

Kuzman I, Orešković K, Schönwald S, Čulig J. Azithromycin in treatment of pneumonias caused by Chlamydia spp: A retrospective study. Int J Clin Pharm Res 1997; 16: 103-107.

Schönwald S, Kuzman I, Car V, Čulig J, Orešković K. Single-dose azithromycin in the treatment of atypical pneumonia: A pilot study. In: Zinner SH (ed.) Infectious disease and therapy, vol. 21, Expanding Indications for the new macrolides, azalides, and streptogramins. New York, US: Marcel Dekker Inc; 1997. p. 634-637.

Kuzman I, Orešković K, Schönwald S, Čulig J, Zrnić T. Azithromycin in the treatment of Q fever. 8th European Congress of Clinical Microbiology and Infectious Diseases, Laussane, Switzerland, May 25-28, 1997.

Kuzman I, Schönwald S, Čulig J, Orešković K. Azithromycin, erythromycin and doxycycline in the treatment of Mycoplasma pneumoniae pneumonia: A retrospective study. In: Berkarda B (ed.) 10th Mediterranean congress of chemotherapy. Bologna, Italy: Monduzzi Editore; 1996, p. 211-214.

Pečur L, Kapitanović S, Sonicki Z, Pavičić F, Spaventi Š, Gluckman JL, Stambrook PJ, Pavelić ZP, Spaventi R, Pavelić K. Prognostic significance of transforming growth factor alpha (TGF-a) in human lung carcinoma: An immunohistochemical study. Anticancer Res 1994; 14: 2839-2844.

Other areas

Pene Dumitrescu T, Anić-Milić T, Orešković K, Padovan J, Brouwer KL, Zuo P, Schmith VD. Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother 2013; 57: 3194-3201.

Polančec D, Vrančić M, Dupont S, Orešković K, Eraković Haber V. Novel flow cytometry method for the detection of neutrophil activation and degranulation in peripheral human whole blood. CYTO 2013: XXVIII Congress of the International society for advancement of cytometry, San Diego, USA, May 19-22, 2013.

Bujak M, Ratkaj I, Baus Lončar M, Spaventi R, Kraljević Pavelić S. Small interfering RNAs: Heralding a new era in gene therapy. In: Kang C (ed.) Gene Therapy – Developments and Future Perspectives. Rijeka, Croatia: InTech; 2011. p. 71-92.

Schmith VD, Zuo P, Padovan J, Stephens K, Kulkarni S, Orešković K. Predicting systemic exposure in humans for a novel drug with low oral bioavailability and local action in the gut. J Clin Pharmacol 2010, 50: 1067.

Sabarinath S, Goyal N, Derendorf H, Orešković K, Schmith VD. Modeling of target lesion scores over time in a psoriasis microplaque assay. Clin Pharmacol Ther 2010; 87 (Suppl. 1): S56-S57.

Šimić P, Buljan Culej J, Orlić I, Grgurević L, Draca N, Spaventi R, Vukičević S. Systemically administered Bone Morphogenic Protein-6 restores bone in aged OVX rats by increasing bone formation and suppressing bone resorption. J Biol Chem 2006; 281: 25509-25521.

Parnham MJ, Bogaards JJP, Schrander F, Schut MW, Orešković K, Mildner B. The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro. Biopharm Drug Dispos 2005; 26: 27-33.

Katušić D, Petriček I, Mandić Z, Petrić I, Salopek-Rabatić J, Kružić V, Orešković K, Šikić J, Petriček G. Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. Am J Ophthalmol 2003; 135: 447-451.

Kapitanović S, Čačev T, Spaventi R, Pavelić K. Submerged gel electrophoresis on Spreadex gels – a new method for APC gene mutations detection. J Mol Med 2001; 79: 333-337.

Reiner Z, Burek V, Goldner V, Jug M, Zrnić T, Orešković K, Čulig J. Prevalence of antibodies to Chlamydia pneumoniae in patients with coronary artery diseases and acute myocardial infarction. Lijec Vjesn 2000; 122: 263-269 [in Croatian].

Kniewald Z, Friganović I, Kniewald J, Novak S, Schonfeld W, Silobrčić V, Spaventi R, Šimić B, Zamola B (eds.): Current studies of biotechnology, vol. 1: Biomedicine. Zagreb, Croatia: Croatian Society of Biotechnology; 2000.

Prpić-Mehičić G, Buntak-Kobler D, Orešković K. Azithromycin versus amoxicillin clavulanate in treatment of odontogenic infections. Int Endod J 1998; 31: 210.

Popović L, Orešković K, Župančić B, Petrunić M, Kunec-Vajić E. The relation between plasma lipid levels and pseudocholinesterase activity in hypothyroidism. Horm Metab Res 1998; 30: 137-140.

Pavić-Sladoljev D, Orešković K. Patient compliance in the treatment of respiratory tract infections. Lijec Vjesn 1997; 119: 193-200 [in Croatian].

Knežević V, Spaventi R, Poljak Lj, Slade N, Švajger A, Pavelić K. p185neu is expressed in yolk sac during rat postimplantation development. J Anatom 1994; 185: 181-187.

Spaventi R, Levanat S. Growth factors and cell cycle control. In: Pavelić K, Spaventi R (guest eds): Molecular aspects of cell cycle, RAD No. 464, Dekaris D (ed.). Zagreb, Croatia: HAZU; 1994. p. 19-39 [in Croatian].

Pavelić K, Spaventi R (guest eds): Molecular aspects of cell cycle, RAD No. 464, Dekaris D (ed.). Zagreb, Croatia: HAZU; 1994 [in Croatian].

Pavelić K, Spaventi R, Pečur L, Spaventi Š. Croatian tumor bank – Significance and perspectives. The embryo of the European network of tumor banks? Hrvatska banka tumora - Značaj i perspektive. Zametak Europske mreže tumorskih banaka? Encyclopaedia moderna 1992; 40: 561-563 [in Croatian].

Spaventi R. Baculoviruses – expression vectors. In: Pavelić K, Spaventi R (eds.) Molecular oncology. Zagreb, Croatia: Globus and HAZU; 1992. p. 79-89 [in Croatian].

Sirotković M, Spaventi R. Homologue recombination. In: Pavelić K, Spaventi R (eds.) Molecular oncology. Zagreb, Croatia: Globus and HAZU; 1992. p. 89-97 [in Croatian].

Pivac (Orešković) K, Kunec-Vajić E. Pseudocholinesterase in alloxan-diabetic rats. Res Commun Chem Pathol Pharmacol 1992; 78: 117-120.

Kunec-Vajić E, Pivac (Orešković) K, Muačević-Katanec D. Enhancement of pseudocholinesterase activity by acetylsalycilic acid in the rat: further evidence for similarities in the mechanism of action of acetylsalycilic acid and certain hypolipidemic drugs. Med Sci Res 1991; 19: 235.

Spaventi R, Antica M, Pavelić K. Insulin and insulin-like growth factor I (IGF I) in early mouse embryogenesis. Development 1990; 108: 491-495.

Spaventi R. Growth factors in embryogenesis. In: Ikić D, Pavelić K, Spaventi R (eds.) Oncogenes and growth factors. Zagreb, Yugoslavia: Globus and JAZU; 1989. p. 125-141 [in Croatian].

Spaventi, R.: Platelet derived growth factor (PDGF). In: Ikić D, Pavelić K, Spaventi R (eds.) Oncogenes and growth factors. Zagreb, Yugoslavia: Globus and JAZU; 1989. p. 163-170 [in Croatian].

Experience built on global level

  • Unique blend of senior management experience across key segments of Pharma industry

Companies

Big Pharma
Mid Pharma (innovative and generic)
Biotech

 

  • WorldgreenSuccesfull management of multinational R&D organisations and teams 
  • WorldNumerous collaborations with Pharma companies, Biotech, academia, non-profit organisations, and various CROs across the globe
  • Deeply embedded in Pharma world with wide network of international contacts

Clients